The Effect of Docetaxel Combined with Neoadjuvant Chemotherapy with Tigio on Disease Control and Serum Tumor Markers in Patients with Advanced Gastric Cancer
Objective To investigate the efficacy of docetaxel combined with Tigioneoadjuvant chemotherapy in patients with advanced gastric cancer.Methods A total of 84 patients with advanced gastric cancer were selected and divided into 2 groups(42 cases each)according to random number table method.The control group received 5-fluorouracil+cisplatin neoadju-vant chemotherapy,and the observation group received docetaxel+Tighio neoadjuvant chemotherapy for 3 cycles,and the disease control effect was analyzed.The changes of serum tumor markers(carbohydrate antigen(CA199)and carcinoembryonic antigen(CEA))before and after 3 cycles of treatment were compared between the 2 groups,and the occurrence of adverse reactions was recorded.Results The disease control rate of the observation group was 54.76％,slightly higher than that of the control group(42.86％),but the difference was not statistically significant(P＞0.05).There was no significant difference in CA199 and CEA values between the 2 groups before treatment(P＞0.05).However,after 3 cycles of treatment,the observation group was lower than control group,the difference was statistically significant(P＜0.05).In addition,there was no significant difference in the in-cidence of adverse reactions between the 2 groups(P＞0.05).Conclusion Docetaxel combined with Tiggio neoadjuvant chemo-therapy can effectively guarantee the therapeutic effect and reduce the levels of CA199 and CEA in patients with advanced gastric cancer,with certain safety.
万方数据
维普
